JPMorgan Chase & Co’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $81 | Sell |
45
-71
| -61% | -$128 | ﹤0.01% | 5973 |
|
|
2025
Q1 | $235 | Buy |
116
+33
| +40% | +$67 | ﹤0.01% | 5906 |
|
|
2024
Q4 | $496 | Buy |
83
+36
| +77% | +$215 | ﹤0.01% | 5747 |
|
|
2024
Q3 | $457 | Hold |
47
| – | – | ﹤0.01% | 5739 |
|
|
2024
Q2 | $959 | Sell |
47
-512
| -92% | -$10.4K | ﹤0.01% | 5602 |
|
|
2024
Q1 | $25.2K | Sell |
559
-235
| -30% | -$10.6K | ﹤0.01% | 5179 |
|
|
2023
Q4 | $37.5K | Sell |
794
-7
| -0.9% | -$330 | ﹤0.01% | 5096 |
|
|
2023
Q3 | $32.4K | Sell |
801
-539
| -40% | -$21.8K | ﹤0.01% | 5030 |
|
|
2023
Q2 | $143K | Buy |
1,340
+259
| +24% | +$27.6K | ﹤0.01% | 4461 |
|
|
2023
Q1 | $322K | Buy |
1,081
+356
| +49% | +$106K | ﹤0.01% | 4054 |
|
|
2022
Q4 | $249K | Buy |
725
+63
| +10% | +$21.6K | ﹤0.01% | 4107 |
|
|
2022
Q3 | $126K | Buy |
662
+13
| +2% | +$2.47K | ﹤0.01% | 4373 |
|
|
2022
Q2 | $137K | Sell |
649
-201
| -24% | -$42.4K | ﹤0.01% | 4491 |
|
|
2022
Q1 | $284K | Buy |
850
+116
| +16% | +$38.8K | ﹤0.01% | 4260 |
|
|
2021
Q4 | $238K | Buy |
734
+49
| +7% | +$15.9K | ﹤0.01% | 4443 |
|
|
2021
Q3 | $332K | Buy |
685
+92
| +16% | +$44.6K | ﹤0.01% | 4168 |
|
|
2021
Q2 | $276K | Buy |
593
+80
| +16% | +$37.2K | ﹤0.01% | 4334 |
|
|
2021
Q1 | $354K | Buy |
513
+150
| +41% | +$104K | ﹤0.01% | 4211 |
|
|
2020
Q4 | $268K | Buy |
363
+90
| +33% | +$66.4K | ﹤0.01% | 4056 |
|
|
2020
Q3 | $188K | Buy |
273
+50
| +22% | +$34.4K | ﹤0.01% | 3759 |
|
|
2020
Q2 | $189K | Buy |
223
+84
| +60% | +$71.2K | ﹤0.01% | 3691 |
|
|
2020
Q1 | $50K | Sell |
139
-433
| -76% | -$156K | ﹤0.01% | 4136 |
|
|
2019
Q4 | $134K | Buy |
572
+448
| +361% | +$105K | ﹤0.01% | 3940 |
|
|
2019
Q3 | $14K | Buy |
124
+20
| +19% | +$2.26K | ﹤0.01% | 4526 |
|
|
2019
Q2 | $18K | Buy |
+104
| New | +$18K | ﹤0.01% | 4538 |
|